- Home
- WY vs RPRX Comparison
WY vs RPRX Comparison
Compare WY & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WY | RPRX |
|---|---|---|
| Founded | 1900 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0B | 16.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | WY | RPRX |
|---|---|---|
| Price | $21.78 | $39.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | $29.78 | ★ $46.00 |
| AVG Volume (30 Days) | ★ 6.0M | 4.3M |
| Earning Date | 10-30-2025 | 11-05-2025 |
| Dividend Yield | ★ 3.87% | 2.21% |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.46 | ★ 1.75 |
| Revenue | ★ $7,072,000,000.00 | $2,349,844,000.00 |
| Revenue This Year | $0.04 | $37.13 |
| Revenue Next Year | $3.97 | $1.48 |
| P/E Ratio | $47.48 | ★ $22.68 |
| Revenue Growth | N/A | ★ 3.70 |
| 52 Week Low | $21.16 | $24.05 |
| 52 Week High | $32.70 | $41.24 |
Technical Indicators
Market Signals| Indicator | WY | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.60 | 57.50 |
| Support Level | $21.22 | $39.24 |
| Resistance Level | $22.47 | $40.50 |
| Average True Range (ATR) | 0.51 | 0.91 |
| MACD | 0.05 | -0.08 |
| Stochastic Oscillator | 38.97 | 76.02 |
Price Performance
Historical ComparisonAbout WY Weyerhaeuser Company
Weyerhaeuser ranks among the world's largest forest product companies. Following the 2016 sale of its pulp business to International Paper, Weyerhaeuser operates three business segments: timberlands, wood products, and real estate. Weyerhaeuser is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities. Earnings from its wood products segment are subject to federal income tax. Weyerhaeuser acquired fellow timber REIT Plum Creek in 2016.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.